Leukemia Posts
Dr. Raanani reflects on caring for hem/onc patients amid war in Israel
Pia Raanani, MD, head of the Institute of Hematology at the Davidoff Cancer Center at the Rabin Medical Center in Israel, shared her experiences as a physician-scientist navigating the challenges […]
Elias Jabbour, MD, talks about obe-cel ASH updates, FDA approval
Dr. Jabbour discusses obecabtagene autoleucel (obe-cel), an autologous CD19-directed chimeric antigen receptor (CAR)-T cell therapy, in relapsed or refractory adult B-cell acute lymphoblastic leukemia during the 66th American Society of […]
Trem-cel enables repeated post-HCT maintenance dosing of gemtuzumab ozogamicin in patients with high-risk AML
Trem-cel enables repeated post-HCT maintenance dosing of gemtuzumab ozogamicin in patients with high-risk AML.
Dr. Yao discusses ASH 2024 study on non-CLL-type MBL
Recorded at the 66th American Society of Hematology Annual Meeting and Exposition, Yuan Yao, MD, MS, discusses the ASH abstract (No.397) titled, “Prevalence, genetic predispositions and clinical consequences of non-CLL-type […]
Fixed-duration regimens outperform SOC in treatment-naïve CLL
Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab improved progression-free survival over fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab in treatment-naïve chronic lymphocytic leukemia (TN CLL), according to an interim analysis of the AMPLIFY […]
Asciminib benefit-risk profile bests other TKIs in CML
Results from the phase 3 ASC4FIRST study presented at the 2024 American Society of Hematology Annual Meeting & Exposition showed that asciminib had a better benefit-risk profile compared with investigator-selected […]
